EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non‐small cell lung cancer patients

Overview of attention for article published in Clinical and Translational Medicine, February 2020

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 4 X users

Citations

dimensions_citation: 20 Dimensions

Readers on

mendeley: 24 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 20 publications that cite this research output.

20

The most recent citing publications are shown below. View all 20 publications that cite this research output on Dimensions.

Uncommon de novo EGFRT790M-Mutant NSCLC characterized with unique genetic Features: Clinical response and acquired resistance to the third-generation EGFR-TKIs treatment

Article in Lung Cancer (March 2024)

Liquid biopsy for the management of NSCLC patients under osimertinib treatment

Article in Critical Reviews in Clinical Laboratory Sciences (February 2024)

The Utility of ctDNA in Lung Cancer Clinical Research and Practice: A Systematic Review and Meta-Analysis of Clinical Studies

Article in Cancer Investigation (June 2023)